Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17158189 | 1.00 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL29457725 | 1.00 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12018159 | 1.00 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5143696 | 1.00 | OPRD1 (0.75) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12017985 | 0.95 | OPRD1 (0.76) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4577159 | 0.95 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4591150 | 0.95 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5078483 | 0.95 | CYP1A2 (0.73) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5082997 | 0.93 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL5083008 | 0.93 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3432884-A1 | COMBINATION FOR TREATING PAIN | Regents of the University of Minnesota (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | claimed |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | claimed |
| EP-1469850-B1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-01-02 | — | — | EP | claimed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | claimed |
| EP-1469850-A4 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | claimed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | claimed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-11529340-B2 | Combination for treating pain | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | disclosed |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | OPRD1 9/4885CYP1A2 2383/4885CYP3A4 3126/4885 |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 656/4885CYP3A4 804/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | OPRD1 6/4885CYP1A2 1796/4885CYP3A4 2957/4885 |
| US-11529340-B2 | Combination for treating pain | OPRL1, ACHE, OPRK1 | OPRD1 6/4885CYP1A2 1796/4885CYP3A4 2957/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 760/4885CYP3A4 675/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 656/4885CYP3A4 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.